Which advanced treatment should be used following the failure of a first-line anti-TNF in patients with rheumatoid arthritis? 15 years of evidence from the Quebec registry RHUMADATA

EULAR 2024

Juvenile Idiopathic Arthritis

Canakinumab is effective as a first-line steroid-free treatment for patients with systemic juvenile idiopathic arthritis

Rheumatoid Arthritis

Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial

Ann Rheum Dis

Lend K, Lampa J, Padyukov L, Hetland ML, Heiberg MS, Nordström DC, Nurmohamed MT, Rudin A, Østergaard M, Haavardsholm EA, Hørslev-Petersen K, Uhlig T, Sokka-Isler T, Gudbjornsson B, Grondal G, Frazzei G, Christiaans J, Wolbink G, Rispens T, Twisk JWR, van Vollenhoven RF

doi: 10.1136/ard-2024-226024

Rheumatoid Arthritis

Five-year follow-up of patients with difficult-to-treat rheumatoid arthritis

Rheumatology (Oxford)

Takanashi S, Takeuchi T, Kaneko Y

doi: 10.1093/rheumatology/keae325

Rheumatoid Arthritis

Association of patient- and hospital-level predictors with patterns of initial treatment in patients with Rheumatoid Arthritis: findings from a national cohort study

Rheumatology (Oxford)

Yang Z, Alveyn E, Russell M, Bechman K, Coalwood C, Price E, Abhishek A, Norton S, Galloway J

doi: 10.1093/rheumatology/keae717

Rheumatoid Arthritis

Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years

Ann Rheum Dis

Burmester GR, Gottenberg JE, Caporali R, Winthrop KL, Tanaka Y, Ekoka Omoruyi EV, Rajendran V, Van Hoek P, Van Beneden K, Takeuchi T, Westhovens R, Aletaha D

doi: 10.1136/ard-2024-225759

Rheumatoid Arthritis

Risk of Incident Heart Failure and Heart Failure Subtypes in Patients with Rheumatoid Arthritis

Arthritis Care Res (Hoboken)

Kawano Y, Weber BN, Weisenfeld D, Jeffway MI, Cai T, McDermott GC, Liu Q, Sparks JA, Stuart J, Joseph J, Cai T, Liao KP

doi: 10.1002/acr.25481

Rheumatoid ArthritisFurther Publications Immunology

Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort

Rheumatology (Oxford)

Nguyen Y, Baron G, Hamamouche N, Belkhir R, Miconnet S, Soubrier M, Hostachy C, Thevenot P, Basch A, Truchetet ME, Claudepierre P, Dernis E, Marotte H, Flipo RM, Brocq O, Morel J, Fautrel B, Salliot C, Saraux A, Leske C, Schaeverbeke T, Ravaud P, Mariette X, Ruyssen-Witrand A, Seror R, ART study group

doi: 10.1093/rheumatology/keae599

Rheumatoid Arthritis

Predictors of arthritis development in individuals at risk of rheumatoid arthritis: a 5-year follow-up study from a large cohort

Ann Rheum Dis

Frazzei G, Landewé RBM, Wagenaar C, van de Stadt LA, van Schaardenburg D, Tas SW, van Vollenhoven RF

doi: 10.1016/j.ard.2025.01.042

Melanoma and Skin Cancer

First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

J Clin Oncol

Long GV, Lipson EJ, Hodi FS, Ascierto PA, Larkin J, Lao C, Grob JJ, Ejzykowicz F, Moshyk A, Garcia-Horton V, Zhou ZY, Xin Y, Palaia J, McDonald L, Keidel S, Salvatore A, Patel D, Sakkal LA, Tawbi H, Schadendorf D

doi: 10.1200/JCO.24.01125

Related content

Canakinumab is effective as a first-line steroid-free treatment for patients with systemic juvenile idiopathic arthritis

Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial

Five-year follow-up of patients with difficult-to-treat rheumatoid arthritis

Association of patient- and hospital-level predictors with patterns of initial treatment in patients with Rheumatoid Arthritis: findings from a national cohort study

Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years

Risk of Incident Heart Failure and Heart Failure Subtypes in Patients with Rheumatoid Arthritis

Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort

Predictors of arthritis development in individuals at risk of rheumatoid arthritis: a 5-year follow-up study from a large cohort

First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data